Neurochemical Research

, Volume 39, Issue 9, pp 1634–1639 | Cite as

Neuroimmunomodulation in Depression: A Review of Inflammatory Cytokines Involved in this Process

  • Helena M. Abelaira
  • Gislaine Z. Réus
  • Fabricia Petronilho
  • Tatiana Barichello
  • João Quevedo
Overview

Abstract

Depression is a debilitating mental disease that affects a large number of people globally; however the pathophysiological mechanisms of this disease remain incompletely understood. Some studies have shown that depression is associated with inflammatory activity, and the mode of action of several antidepressants appears to involve immunomodulation. In this case, the induction of a pro-inflammatory state in healthy or depressive subjects induces a ‘sickness behaviour’ resembling depressive symptomatology. Potential mechanisms of pro-inflammatory cytokines are effects on monoamine levels, disruption of the hypothalamic–pituitary–adrenal axis, activation of the pathological microglial cells, such as the macrophages and alterations in neuroplasticity and brain functions. Thus, this review will highlight the role of inflammation in depression, the possible mechanisms involved, and also explore effective treatments that act on the immune system.

Keywords

Cytokines Inflammation Antidepressants Depression 

Introduction

Depression is a mood disorder that may ultimately cause severe impairment in occupational, social, or other important areas of functioning. The disease also has high mortality rate, as the indexes of individuals who die by suicide reach 15 % [1]. The etiology of depression is associated with stressful life events, personality, gender, illness, family history, loneliness as well as alcohol and drugs abuse [2]. Although the pathophysiology of depression is not yet fully known, this disorder may be involved with changes in the expression of neurotransmitters, the hypothalamus–adrenal–pituitary (HPA) axis, genes and structural changes within the brain. Treatment of depression is generally safe and effective, but it is far from ideal, since only 60–70 % of patients using antidepressants are positive about their therapeutic efficacy, in addition to its various side effects [3]. Therefore it is necessary to look beyond currently characterized neurotransmitter systems to understand the pathophysiology of depression in order to produce more effective treatments in the long-term. Major depression has been shown to be associated with activation of the inflammatory response. These changes include increased numbers of peripheral leucocytes including monocytes and neutrophils [4]. Positive acute phase proteins including C-reactive protein are increased [5] while negative acute phase proteins are decreased, e.g. albumin [6]. This acute phase response is an integral part of the inflammatory response and its purpose is to enable protein mobilization, which serves to limit tissue damage and stimulate repair [7]. Smith [8] put forward the ‘macrophage theory of depression’ in which he proposed that excessive secretion of macrophage cytokines such as as interleukin (IL)-1, tumor necrosis factor (TNF-α) and interferon (INF-γ) were associated with major depression and these alteration may contribute to the dysfunction of the serotonergic and noradrenergic systems. Thus, this review will highlight the role of inflammation in depression and the possible mechanisms involved, besides exploring any effective treatments that act on the immune system.
Fig. 1

Representation of how cytokines lead to the development of depressive disorder. Cytokines that are produced peripherally can reach the brain through leakage regions of blood brain barrier, with cytokine binding to specific molecules expressed on the endothelium of the brain, and other factors, which lead to the cytokines affecting brain functions. This in turn, leads to the development of depressive disorder

The Inflammatory System and Its Function

The immune system is well known for its function in defending a host against microbial invasion [9]. It is conceptually divided into the innate and adaptive immune systems [10], that consist of cells and molecules that work together, in concert, to fight against microbial infection and to maintain homeostasis. In this context, the innate immunity represents a rapid and stereotyped response to a large number of limited stimuli. It is represented by physical, chemical and biological systems, using specialized cells such as macrophages, neutrophils, dendritic cells, natural killer cells [11] and soluble molecules present in all individuals [12]. These release inflammatory mediators and activate the complement system, as well as stimulating the activation of acute phase proteins, that’s when the pro-inflammatory cytokines are released, and the vascular system and inflammatory cells are activated, thus characterizing innate immunity [13]. In addition to this, these elements contribute to the activation of the adaptive immune system [10]. The response of the adaptive immune system serves to create and maintain the memory of the immune system [14]; furthermore, it is antigen-specific, and is based on the antigen-specific receptors on the surfaces of T and B lymphocytes [9]. T-lymphocytes produce the cellular response and maintain the immune response through the release of cytokines, mainly IL-2, to attract more macrophages, neutrophils and lymphocytes. Therewith, the B-lymphocytes are attracted and stimulated by these cytokines to induce a humoral response whereby antibodies are produced against the identified pathogens [15]. Cytokines comprise a heterogeneous group of messenger molecules that are produced by immunocompetent cells, such as lymphocytes and macrophages, which are secreted by astrocytes and microglia during human fetal development, suggesting a role of cytokines in the modulation of nervous system development [16, 17]. They are present at low concentrations in the nervous system under physiological conditions, however, in pathological conditions, they are able to increase their concentrations up to a hundred times [18]. Although their specific activities and concentrations may vary, cytokines can be divided into two groups, the pro-inflammatory and anti-inflammatory cytokines. The first group contains cytokines that are classified by being directly involved in the inflammatory process, such as interleukin (IL)—1β, IL -6, interferon (IFN) -γ and TNF—α. The second group includes IL-4, IL-10 and IL-13, which are known to decrease the inflammatory response by producing pro-inflammatory mediators. However, there are some cytokines, such as IL-8, which are able to perform both tasks, depending on the concentration in which this cytokine is synthesized [15, 16]. In the end, the cytokines and chemical factors produced during the inflammatory response serve as excellent biomarkers when investigating the potential relationship between inflammation and mood disorders.

The Role of Cytokines Produced by Innate Immunity in Depression

It has been established that cytokines that are produced peripherally can reach the brain through leakage regions of blood brain barrier, cytokine binding to specific molecules expressed on the endothelium of the brain, and other factors, that lead to the cytokines affecting brain functions [19, 20], and thereby causing the development of depressive disorder. The hypothesis that cytokines are related to depressive disorder was first proposed by Smith [8] and Maes [21]. These studies showed that in patients with chronic depression, there was an increase of inflammatory markers in the blood, but these results were overshadowed by the advancement and success of selective serotonin reuptake inhibitors and other monoaminergic-based treatments for depression. However, many studies have shown a relationship between an increased incidence of mood episodes and elevated levels of inflammatory markers, such as prostaglandin E2 (PGE2), TNF-α, IL-1β, IL-2, and IL-6 in peripheral blood and cerebral spinal fluid in major depression [22, 23, 24, 25, 26, 27].

TNF-α is of particular interest as it’s a pro-inflammatory cytokine that been shown to contribute to the pathogenesis of depression [28, 29], and may influence central serotonergic homeostasis through the modulation of glial localized serotonin transporter activity, allowing a possible link of depressive symptoms with chronic inflammatory diseases [30]. Moreover, Reichenberg et al. [31] showed that an experimental stimulation of TNF-α production leads to depression-like emotional and cognitive disturbances in humans. Furthermore, a considerable number of studies showed elevated serum levels of TNF-α in depressed patients [32, 33, 34, 35, 36], while one study reported unchanged levels of these cytokine [37]. In animals, intracerebroventricular injections of lipopolysaccharide (LPS) or this pro-inflammatory cytokine are sufficient to produce depressive-like behavior [38, 39]. Moreover, intracerebroventricular administration of TNF-α antagonist [40, 41, 42, 43] is sufficiently capable of reversing sickness and depressive-like behaviors that usually occur in systemic inflammation. It has been postulated on the basis of in vitro as well as in vivo studies, that the therapeutic action of antidepressants may be partially caused by their influence on cytokine production in addition to their direct effect on monoaminergic neurotransmission. In this way, some antidepressants have been shown to decrease TNF-α production in depressed patients [44, 45]. Still, Bayramgurler et al. [46] showed that in animals, etanercept, a TNF-α receptor antagonist, presented antidepressant and anxiolytic effects. In humans, the anti- TNF-α antibody, infliximab has been shown to reduce depressive symptoms in depressed patients that were resistant to antidepressant treatments [47]; and the potentially beneficial antidepressant effect of infliximab depends on the baseline of inflammatory levels [48]. Besides TNF-α, which is known to act in the immunoregulation of inflammatory processes, studies suggest that cytokine IL-1β is also involved in neuroinflammation [19, 49]. Indeed, it has been noted that the pathophysiological levels of IL-1β may regulate synaptic plasticity and behavioral systems, beyond having detrimental effects on hippocampal-dependent memory and learning processes [50, 51, 52, 53, 54, 55, 56].

Behind the various factors associated with inflammation, cytokine IL-1β appears to have particularly strong associations with depression [57, 58, 59, 60]. In fact, recent studies have reported the association between the polymorphism of IL-1β and major depression [49, 61], and they have even implicated the IL-β gene polymorphism (specifically its rs16944 variant, which results in the increased IL1-β levels) in the lack of response to selective serotonin reuptake inhibitors (SSRI) [62]. Furthermore, IL-1β cytokine is known to modulate the function of the HPA axis [60, 63]. For example, intra-hippocampal administration of recombinant IL1-β in rats leads to an increased plasma cortisol level [57]. In turn, the dysregulation of the HPA axis has been regarded as a neuroendocrine hallmark of chronic stress [64, 65] and has been used as a diagnostic tool in depression [66]. In this way, Goshen et al. [54] showed that chronic mild stress induced depressive-like symptoms concomitantly with an increase in IL-1β expression in the hippocampus, but in mice which possessed a deletion of the IL-1β receptor or a restricted overexpression of the IL-1β antagonist, exhibited no behavioral or neuroendocrine alterations after stress induction. Some studies also showed that administration of cytokines such as IL-1β, or the activation of macrophages and inflammatory cells via treatment with LPS causes behavioral and performance changes related with ‘sickness behaviour’ [54, 67, 68, 69]. In addition, in healthy human volunteers, depression, anxiety and memory impairment were associated with immune activation by the bacterial endotoxin LPS and were correlated with serum IL-1β and TNF-α levels induced by that treatment [70]. Also, Levine et al. [32] showed that depressed patients had higher IL-1β levels and no change in TNF-α compared with control group. IL-6 is a pro-inflammatory cytokine and different to TNF- and IL-1β. The highest levels of IL-6 production are found in adipocytes, highlighting the nexus between diet, obesity and depression, although central nervous system cells and immune cells are also a significant source [71]. Some pro-inflammatory cytokines such as IFN-γ and TNF-α can induce IL-6 in the inflammatory process [71, 72]. The increase of IL-6 in depression is associated with increased activity of the HPA axis, which in turn, increases the cortisol levels leading to activation of tryptophan 2,3-dioxygenase and decreased availability of tryptophan into the synthesis of serotonin, N-acetylserotonin and melatonin [71], thus, IL-6 has a role in the co-ordination of important biological pathways underlying stress and stress induced depression. In this case, some studies have shown elevated levels of IL-6 in the cerebrospinal fluid (CSF) and plasma of suicide attempters with a diagnosis of major depressive disorder and in patients who are refractory to selective serotonin reuptake inhibitor or serotonin–norepinephrine reuptake inhibitor treatment [24, 73]. However, treatment for the normalization of the high levels of this cytokine in plasma, blood and CSF yet seems contradictory.

Interestingly, several studies have been shown that in some cases, antidepressants reduce pro-inflammatory cytokines profiles and inflammatory markers in patients with depression [74, 75]. In fact, Himmerich et al. [76] found that blood levels of IL-1β became undetectable in patients with depression after treatment with antidepressants. Still, Ohgi et al. [77] observed that pretreatment with paroxetine, fluoxetine, venlafaxine and duloxetine in male BALB/c mice decreased the TNF-α levels in serum after the administration of LPS. Similarly, Réus et al. [78] showed that treatment with the antidepressant imipramine reduced the TNF-α and IL-1β levels in the serum and CSF induced by maternal deprivation in adult rats. In addition to antidepressants decreasing the levels of pro-inflammatory cytokines, the inhibition of production of pro-inflammatory cytokines, such as, TNF-α and IL-1β by celexocib, an anti-inflammatory, also induced a rapid antidepressant response and prevented cognitive decline in patients with major depressive disorder [79]. Besides celecoxib, other types of anti-inflammatory drugs have also been shown to have antidepressant-like effects associated with their anti-inflammatory actions, such as, minocycline, which is an antibiotic with an anti-inflammatory profile that has antidepressant like effects [80, 81]. Similar to the anti-inflammatory infliximab which is used in the treatment of psoriasis and related to chronic inflammation conditions, minocycline has mood-elevating effects before decreasing TNF-α levels [82].

Some depressed patients showed a decrease in the levels of IL-6 with antidepressants, but others who are resistant to treatment with antidepressants retained elevated levels of IL-6 in their plasma, suggesting a potential role for IL-6 in the treatment of treatment resistant depression [83, 84, 85]. IL-6 levels also appear increased in animal models of depression [86] and antidepressants decrease the levels of the pro-inflammatory cytokine IL-6 in animal models, as well as in brain cultures and in humans [87]. Furthermore, Anderson et al. [71] suggests that monitoring IL-6 levels may provide an indicator of emerging alterations in the biological basis of depression.

Futhermore, in addition to these antidepressant effects, recent studies have reported anti-inflammatory effects in murine models of autoimmune disease like collagen induced arthritis or EAE [88]. SSRI and SNRI (selective serotonin/norepinephrine inhibitors) have been demonstrated to ameliorate clinical autoimmune disease and to decrease inflammation and inflammatory cytokine production in this context [89, 90].

Conclusion

A number of studies have shown an association between markers of the inflammatory process and major depressive disorder. In this way, disturbances in HPA function that lead to inflammatory system alterations, increasing the levels of the cytokines IL-1β, IL-6 and TNF-α, have long been recognized in depression. However, more studies are needed to characterize the mechanisms that lead to these alterations in the inflammatory markers within depression and their participation in antidepressant mechanisms, and so, further research in this area could reveal the great potential for the identification of new therapeutic targets for the development of antidepressant drugs.

Notes

Acknowledgments

Laboratory of Neurosciences (Brazil) is a center within the National Institute for Translational Medicine (INCT-TM) and is also a member of the Center of Excellence in Applied Neurosciences of Santa Catarina (NENASC). This research was supported by grants from CNPq (JQ and GZR), FAPESC (JQ), Instituto Cérebro e Mente, UNESC (JQ and TB), and and L´Oréal/UNESCO/ABC Brazil Fellowship for Women in Science 2011 (GZR). JQ and TB are CNPq Research Fellows. HMA has CAPES studentships. We thank Allan M. Colladel for making the Fig. 1.

References

  1. 1.
    Duman RS (1998) Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 44:324–335PubMedCrossRefGoogle Scholar
  2. 2.
    Patel A (2013) Review: the role of inflammation in depression. Psychiatr Danub 25:216–223Google Scholar
  3. 3.
    Nemeroff CB, Owens MJ (2002) Treatment of mood disorders. Nat Neurosci 5:1068–1070PubMedCrossRefGoogle Scholar
  4. 4.
    Herbert TB, Cohen S, Marsland AL et al (1994) Cardiovascular reactivity and the course of immune response to an acute psychological stressor. Psychosom Med 56:337–344PubMedCrossRefGoogle Scholar
  5. 5.
    Maes M (2001) The immunoregulatory effect of antidepressants. Hum Psychopharmacol Clin Exp 16:95–103CrossRefGoogle Scholar
  6. 6.
    Maes M (1999) Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461:25–46PubMedCrossRefGoogle Scholar
  7. 7.
    Kushner I (1982) The phenomena of the acute phase response. Ann N Y Sci 389:39–48CrossRefGoogle Scholar
  8. 8.
    Smith RS (1991) The macrophage theory of depression. Med Hypotheses 35:298–306PubMedCrossRefGoogle Scholar
  9. 9.
    Sirisinha S (2011) Insight into the mechanisms regulating immune homeostasis in health and disease. Asian Pac J Allergy Immunol 1:1–14CrossRefGoogle Scholar
  10. 10.
    Suvisaari J, Mantere O (2013) Inflammation theories in psychotic disorders: a critical review. Infect Disord Drug Targets 13:59–70PubMedCrossRefGoogle Scholar
  11. 11.
    Suvisaari J, Loo BM, Saarni SE, Haukka J, Perälä J, Saarni SI, Viertiö S, Partti K, Lönnqvist J, Jula A (2011) Inflammation in psychotic disorders: a population-based study. Psychiatry Res 189:305–311PubMedCrossRefGoogle Scholar
  12. 12.
    Cruvinel WM, Mesquita DJ, Araújo JAP, Catelan TTT, Souza AW, Silva NP, Andrade LEC (2010) Sistema imunitário—parte i fundamentos da imunidade inata com ênfase nos mecanismos moleculares e celulares da resposta inflamatória. Rev Bras Reumatol 50:434–461Google Scholar
  13. 13.
    Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ (2005) Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B 6:1045–1056PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Abbas AK, Lichtman AH, Pillai S (2012) Cellular and molecular immunology, 7th edn. Elsevier Saunders, Philadelphia, p 864Google Scholar
  15. 15.
    Janeway CA, Travers P (1997) Immunobiology. The immune system in health and disease, 3rd edn. Current Biol/Garland Publishing, New YorkGoogle Scholar
  16. 16.
    Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157:683–694PubMedCrossRefGoogle Scholar
  17. 17.
    Rezaie P, Trillo-Pazos G, Everall IP, Male DK (2002) Expression of beta-chemokines and chemokine receptors in human fetal astrocyte and microglial co-cultures: potential role of chemokines in the developing CNS. Glia 37:64–75PubMedCrossRefGoogle Scholar
  18. 18.
    Lee YB, Nagai A, Kim SU (2002) Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 69:94–103PubMedCrossRefGoogle Scholar
  19. 19.
    Khairova RA, Machado-Vieira R, Du J, Manji HK (2009) A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 12:561–578PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR (2006) Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 30:899–905PubMedCrossRefGoogle Scholar
  21. 21.
    Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19:11–38PubMedCrossRefGoogle Scholar
  22. 22.
    Felger JC, Lotrich FE (2013) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246:199–229PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457PubMedCrossRefGoogle Scholar
  24. 24.
    Kling MA, Alesci S, Csako G, Costello R, Luckenbaugh DA, Bonne O et al (2007) Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry 62:309–313PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Ford DE, Erlinger TP (2004) Depression and C-reactive protein in US adults: data from the third national health and nutrition examination survey. Arch Intern Med 164:1010–1014PubMedCrossRefGoogle Scholar
  26. 26.
    Danner M, Kasl SV, Abramson JL, Vaccarino V (2003) Association between depression and elevated C-reactive protein. Psychosom Med 65:347–356PubMedCrossRefGoogle Scholar
  27. 27.
    Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J et al (2002) Inflammation and coagulation factors in persons N 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 89:419–424PubMedCrossRefGoogle Scholar
  28. 28.
    Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S et al (2008) Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 23:421–429PubMedCrossRefGoogle Scholar
  29. 29.
    Simen BB, Duman CH, Simen AA, Duman RS (2006) TNF[alpha] signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 59:775–785PubMedCrossRefGoogle Scholar
  30. 30.
    Malynn S, Campos-Torres A, Moynagh P, Haase J (2013) The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem Res 38:694–704PubMedCrossRefGoogle Scholar
  31. 31.
    Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al (2001) Cytokineassociated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58:445–452PubMedCrossRefGoogle Scholar
  32. 32.
    Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V (1999) Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiol 40:171–176CrossRefGoogle Scholar
  33. 33.
    Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H (2000) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol 22:370–379CrossRefGoogle Scholar
  34. 34.
    Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M (2001) Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 11:203–208PubMedCrossRefGoogle Scholar
  35. 35.
    Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S et al (2003) Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol Psychiatry 54:566–572PubMedCrossRefGoogle Scholar
  36. 36.
    Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E (2003) Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacol 170:429–433CrossRefGoogle Scholar
  37. 37.
    Marques-Deak AH, Neto FL, Dominguez WV, Solis AC, Kurcgant D, Sato F et al (2007) Cytokine profiles in women with different subtypes of major depressive disorder. J Psychiatr Res 41:152–159PubMedCrossRefGoogle Scholar
  38. 38.
    Palin K, McCusker RH, Strle K, Moos F, Dantzer R, Kelley KW (2008) Tumor necrosis factor-a-induced sickness behavior is impaired by central administration of an inhibitor of c-jun N-terminal kinase. Psychopharmacol 197:629–635CrossRefGoogle Scholar
  39. 39.
    Fu X, Zunich SM, O’Connor JC, Kavelaars A, Dantzer R, Kelley KW (2010) Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3-dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation 7:43PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Kent S, Bluthé RM, Kelley KW, Dantzer R (1992) Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13:24–28PubMedCrossRefGoogle Scholar
  41. 41.
    Kent S, Bluthé RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ, Vannice JL (1992) Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA 89:9117–9120PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Kent S, Kelley KW, Dantzer R (1992) Effects of lipopolysaccharide on foodmotivated behavior in the rat are not blocked by an interleukin-1 receptor antagonist. Neurosci Lett 145:83–86PubMedCrossRefGoogle Scholar
  43. 43.
    Bluthé RM, Michaud B, Poli V, Dantzer R (2000) Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol Behav 70:367–373PubMedCrossRefGoogle Scholar
  44. 44.
    Ignatowski TA, Chou RC, Spengler RN (1996) Changes in noradrenergic sensitivity to tumor necrosis factor-alpha in brains of rats administered clonidine. J Neuroimmunol 70:55–63PubMedCrossRefGoogle Scholar
  45. 45.
    Nickola TJ, Ignatowski TA, Reynolds JL, Spengler RN (2001) Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-alpha mRNA and alpha(2)-adrenergic receptor sensitivity. J Pharmacol Exp Ther 297:680–687PubMedGoogle Scholar
  46. 46.
    Bayramg€urler D, Karson A, Ozer C, Utkan T (2013) Effects of longterm etanercept treatment on anxiety- and depression-like neurobehaviors in rats. Physiol Behav 119C:145–148CrossRefGoogle Scholar
  47. 47.
    Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31–41PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Kraneveld AD, de Theije CG, van Heesch F, Borre Y, de Kivit S, Olivier B, Korte M, Garssen J (2014) The neuro-immune axis: prospect for novel treatments for mental disorders. Basic Clin Pharmacol Toxicol 114:128–136PubMedCrossRefGoogle Scholar
  49. 49.
    Pineda EA, Hensler JG, Sankar R, Shin D, Burke TF, Mazarati AM (2012) Interleukin-1β causes fluoxetine resistance in an animal model of epilepsy-associated depression. Neurotherapeutics 9:477–485PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Barrientos RM, Higgins EA, Sprunger DB, Watkins LR, Rudy JW, Maier SF (2002) Memory for context is impaired by a post context exposure injection of interleukin-1 beta into dorsal hippocampus. Behav Brain Res 134:291–298PubMedCrossRefGoogle Scholar
  51. 51.
    Bellinger FP, Madamba S, Siggins GR (1993) Interleukin 1 beta inhibits synaptic strength and long-term potentiation in the rat CA1 hippocampus. Brain Res 628:227–234PubMedCrossRefGoogle Scholar
  52. 52.
    Curran B, O’Connor JJ (2001) The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience 108:83–90PubMedCrossRefGoogle Scholar
  53. 53.
    Gibertini M, Newton C, Friedman H, Klein TW (1995) Spatial learning impairment in mice infected with Legionella pneumophila or administered exogenous interleukin-1-beta. Brain Behav Immun 9:113–128PubMedCrossRefGoogle Scholar
  54. 54.
    Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, Yirmiya R (2008) Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 13:717–728PubMedCrossRefGoogle Scholar
  55. 55.
    Oitzl MS, van Oers H, Schobitz B, de Kloet ER (1993) Interleukin-1 beta, but not interleukin-6, impairs spatial navigation learning. Brain Res 613:160–163PubMedCrossRefGoogle Scholar
  56. 56.
    Pugh CR, Nguyen KT, Gonyea JL, Fleshner M, Wakins LR, Maier SF, Rudy JW (1999) Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res 106:109–118PubMedCrossRefGoogle Scholar
  57. 57.
    Parsadaniantz SM, Batsche E, Gegout-Pottie P et al (1997) Effects of continuous infusion of interleukin 1 beta on corticotropin-releasing hormone (CRH), CRH receptors, proopiomelanocortin gene expression and secretion of corticotropin, beta-endorphin and corticosterone. Neuroendocrinology 65:53–63PubMedCrossRefGoogle Scholar
  58. 58.
    Konsman JP, Veeneman J, Combe C, Poole S, Luheshi GN, Dantzer R (2008) Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide. Eur J Neurosci 28:2499–2510PubMedCrossRefGoogle Scholar
  59. 59.
    Dantzer R (2009) Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 29:247–264PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Goshen I, Yirmiya R (2009) Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol 30:30–45PubMedCrossRefGoogle Scholar
  61. 61.
    Borkowska P, Kucia K, Rzezniczek S et al (2011) Interleukin-1beta promoter (-31T/C and -511C/T) polymorphisms in major recurrent depression. J Mol Neurosci 44:12–16PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Baune BT, Dannlowski U, Domschke K et al (2010) The interleukin 1 beta (IL-1β) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry 67:543–549PubMedCrossRefGoogle Scholar
  63. 63.
    Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T (2011) IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun 25:1281–1289PubMedCrossRefGoogle Scholar
  64. 64.
    Herman JP, Cullinan WE (1997) Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 20:78–84PubMedCrossRefGoogle Scholar
  65. 65.
    Yu S, Holsboer F, Almeida OF (2008) Neuronal actions of glucocorticoids: focus on depression. J Steroid Biochem Mol Biol 108:300–309PubMedCrossRefGoogle Scholar
  66. 66.
    Watson S, Gallagher P, Smith MS, Ferrier IN, Young AH (2006) The DEX/CRH test-is it better than the DST? Psychoneuroendocrinology 31:889–894PubMedCrossRefGoogle Scholar
  67. 67.
    Dantzer R (2001) Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 933:222–234PubMedCrossRefGoogle Scholar
  68. 68.
    Larson SJ, Dunn AJ (2001) Behavioral effects of cytokines. Brain Behav Immun 15:371–387PubMedCrossRefGoogle Scholar
  69. 69.
    Maier SF, Watkins LR (1998) Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 105:83–107PubMedCrossRefGoogle Scholar
  70. 70.
    Yirmiya R (2000) Depression in medical illness: the role of the immune system. West J Med 173:333–336PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Anderson G, Kubera M, Duda W, Lasoń W, Berk M, Maes M (2013) Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin andneuroprogression. Pharmacol Rep 65:1647–1654PubMedCrossRefGoogle Scholar
  72. 72.
    Dandrea M, Donadelli M, Costanzo C, Scarpa A, Palmieri M (2009) MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines. Nucleic Acids Res 37:6681–6690PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H (1997) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9:853–858PubMedCrossRefGoogle Scholar
  74. 74.
    Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K et al (2005) IL-6 levels decrease SSRI treatment in patients with major depression. Hum Psychopharmacol 20:473–476PubMedCrossRefGoogle Scholar
  75. 75.
    O’Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG (2007) Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 41:326–331PubMedCrossRefGoogle Scholar
  76. 76.
    Himmerich H, Milenovic S, Fulda S, Plumakers B, Sheldrick AJ, Michel TM et al (2010) Regulatory T cells increased while IL-1beta decreased during antidepressant therapy. J Psychiatr Res 44:1052–1057PubMedCrossRefGoogle Scholar
  77. 77.
    Ohgi Y, Futamura T, Kikuchi T, Hashimoto K (2013) Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 103:853–859PubMedCrossRefGoogle Scholar
  78. 78.
    Réus GZ, Dos Santos MA, Abelaira HM, Ribeiro KF, Petronilho F, Vuolo F, Colpo GD, Pfaffenseller B, Kapczinski F, Dal-Pizzol F, Quevedo J (2013) Imipramine reverses alterations in cytokines and BDNF levels induced by maternal deprivation in adult rats. Behav Brain Res 242:40–46PubMedCrossRefGoogle Scholar
  79. 79.
    Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23:87–94PubMedCrossRefGoogle Scholar
  80. 80.
    Levine J, Cholestoy A, Zimmerman J (1996) Possible antidepressant effect of minocycline. Am J Psychiatry 153:582PubMedGoogle Scholar
  81. 81.
    Molina-Hernandez M, Tellez-Alcantara NP, Perez-garcia J et al (2008) Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 32:380–386PubMedCrossRefGoogle Scholar
  82. 82.
    Lichtenstein GR, Bola M, Man C, DeWoody K, Schaible T (2002) Infliximab improves the quality of life in patients with Crohn’s disease. Inflamm Bowel Dis 8:237–243PubMedCrossRefGoogle Scholar
  83. 83.
    Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L et al (2009) Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 66:287–292PubMedCrossRefGoogle Scholar
  84. 84.
    Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J (2009) Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 33:722–726PubMedCrossRefGoogle Scholar
  85. 85.
    Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G et al (2006) Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 67:1760–1766PubMedCrossRefGoogle Scholar
  86. 86.
    Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36:764–785PubMedCrossRefGoogle Scholar
  87. 87.
    Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M (2011) In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35:744–759PubMedCrossRefGoogle Scholar
  88. 88.
    Shenoy AR, Dehmel T, Stettner M, Kremer D, Kieseier BC, Hartung HP, Hofstetter HH (2013) Citalopram suppresses thymocyte cytokine production. J Neuroimmunol 262:46–52PubMedCrossRefGoogle Scholar
  89. 89.
    Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B (2009) The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol 12:525–536PubMedCrossRefGoogle Scholar
  90. 90.
    Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R (2010) Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum 62:683–693PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Helena M. Abelaira
    • 1
  • Gislaine Z. Réus
    • 1
    • 2
  • Fabricia Petronilho
    • 2
    • 3
  • Tatiana Barichello
    • 1
    • 2
  • João Quevedo
    • 1
    • 2
  1. 1.Laboratório de Neurociências, Unidade Acadêmica de Ciências da Saúde, Programa de Pós-Graduação em Ciências da SaúdeUniversidade do Extremo Sul CatarinenseCriciúmaBrazil
  2. 2.Center for Experimental Models in Psychiatry, Department of Psychiatry and Behavioral SciencesThe University of Texas Medical School at HoustonHoustonUSA
  3. 3.Laboratório de Fisiopatologia Clínica e Experimental, Programa de Pós-graduação em Ciências da SaúdeUniversidade do Sul de Santa CatarinaTubarãoBrazil

Personalised recommendations